Biotech Mailbag 2008 Review

A Mailbag review column wouldn't be complete without a mention of Introgen Therapeutics(INGN.PK Quote), which provided much comedic and instructional fodder for how to avoid bad biotech investments. Introgen is now in bankruptcy, alas, so the Mailbag will have to find new biotech stocks to kick around.

Biotech loves controversy, and so does the Mailbag, so in 2009, I hope to continue to answer your questions, absorb your criticisms and savor your praise. More than anything, I hope the Mailbag helps to make some sense out of biotech investing. Thanks again for all your emails this year, and my apologies for the many emails I couldn't find time to answer. I'll try to get to as many of them as possible in 2009.

Happy New Year and, please, keep those emails coming.